维奈克拉治疗急性髓系白血病研究进展 |
| |
引用本文: | 魏旭东,陈琳.维奈克拉治疗急性髓系白血病研究进展[J].白血病.淋巴瘤,2021,30(5):257-261. |
| |
作者姓名: | 魏旭东 陈琳 |
| |
作者单位: | 郑州大学附属肿瘤医院 河南省肿瘤医院血液科,郑州 450003 |
| |
摘 要: | 维奈克拉的应用是近年来治疗急性髓系白血病(AML)的重要突破。诱导凋亡药物联合去甲基化药物这一非化疗手段应用于AML的治疗,给老年或不能耐受强化疗的患者带来了长期生存的希望,但目前仍有一部分患者会对含维奈克拉的方案出现耐药。文章结合第62届美国血液学会(ASH)年会报道对维奈克拉治疗AML的新进展进行介绍。
|
关 键 词: | 白血病,髓样,急性 维奈克拉 分子靶向治疗 |
Progress of venetoclax in treatment of acute myeloid leukemia |
| |
Abstract: | Venetoclax is an important breakthrough in the treatment of acute myeloid leukemia (AML) in recent years. A chemo-free treatment of inducing apoptosis drugs combined with hypomethylating agents is used in the management of AML, which brings hope of long-term survival for the elderly patients or patients who cannot tolerate intensive chemotherapy. However, there are still some patients who are resistant to venetoclax-based regimens. This article introduces the new progress of venetoclax in the treatment of AML in combination with reports at the 62nd American Society of Hematology (ASH) Annual Meeting. |
| |
Keywords: | Leukemia myeloid acute Venetoclax Molecular targeted therapy |
本文献已被 万方数据 等数据库收录! |